Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1
- PMID: 16567993
- DOI: 10.1097/01.inf.0000207492.97867.15
Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1
Abstract
Live varicella virus vaccine was administered to 10 stable human immunodeficiency virus type 1 (HIV-1)-infected children. Subjects were monitored for adverse reactions, HIV-1 plasma levels, CD4 T cell counts and immune responses. The vaccine was well-tolerated. Varicella-zoster virus-specific lymphocyte proliferative responses were detected in all subjects by 4 weeks and in 9 of 10 subjects 1 year after vaccination.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
- Medical
- Research Materials
 
        